HIMS

NYSE Healthcare

Hims & Hers Health, Inc. Class A Common Stock

Drug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

๐Ÿ“Š Market Data
Price$27.41
Volume14,284,516
Market Cap6.33B
Beta2.310
RSI (14-Day)65.3
200-Day MA$37.32
50-Day MA$22.07
52-Week High$70.43
52-Week Low$13.74
P/E Ratio53.75
Forward P/E19.87
Price / Book11.52
๐ŸŽฏ Investment Strategy Scores

HIMS scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 94/100โ–ฒ +1
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 83/100โ–ผ -1
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 73/100โ–ผ -2
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (94/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find HIMS in your text

Paste any article, transcript, or post โ€” the tool will extract HIMS and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.